Suppr超能文献

Ghrelin 调节脂肪组织代谢:在肝脂肪变性中的作用。

Ghrelin regulates adipose tissue metabolism: Role in hepatic steatosis.

机构信息

Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Research Service, Veterans' Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, 68105, USA.

Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 68198, USA; Research Service, Veterans' Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, 68105, USA.

出版信息

Chem Biol Interact. 2020 May 1;322:109059. doi: 10.1016/j.cbi.2020.109059. Epub 2020 Mar 11.

Abstract

Fatty liver is the earliest and most common response of the liver to consumption of excessive alcohol. Steatosis can predispose the fatty liver to develop progressive liver damage. Chief among the many mechanisms involved in development of hepatic steatosis is dysregulation of insulin-mediated adipose tissue metabolism. Particularly, it is the enhanced adipose lipolysis-derived free fatty acids and their delivery to the liver that ultimately results in hepatic steatosis. The adipose-liver axis is modulated by hormones, particularly insulin and adiponectin. In recent studies, we demonstrated that an alcohol-induced increase in serum ghrelin levels impairs insulin secretion from pancreatic β-cells. The consequent reduction in circulating insulin levels promotes adipose lipolysis and mobilization of fatty acids to the liver to ultimately contribute to hepatic steatosis. Because many tissues, including adipose tissue, express ghrelin receptor we hypothesized that ghrelin may directly affect energy metabolism in adipocytes. We have exciting new preliminary data which shows that treatment of premature 3T3-L1 adipocytes with ghrelin impairs adipocyte differentiation and inhibits lipid accumulation in the tissue designed to store energy in the form of fat. We further observed that ghrelin treatment of differentiated adipocytes significantly inhibited secretion of adiponectin, a hepatoprotective hormone that reduces lipid synthesis and promotes lipid oxidation. These results were corroborated by our observations of a significant increase in serum adiponectin levels in ethanol-fed rats treated with a ghrelin receptor antagonist verses the un-treated ethanol-fed rats. Interestingly, in adipocytes, ghrelin also increases secretion of interleukin-6 (IL-6) and CCL2 (chemokine [C-C motif] ligand 2), cytokines which promote hepatic inflammation and progression of liver disease. To summarize, the alcohol-induced increase in serum ghrelin levels dysregulates adipose-liver interaction and promotes hepatic steatosis by increasing the free fatty acid released from adipose for hepatic uptake, and by altering adiponectin and cytokine secretion. Taken together, our data indicates that targeting the activity of ghrelin may be a powerful treatment strategy.

摘要

脂肪肝是肝脏对过量饮酒的最早和最常见的反应。脂肪变性可使脂肪肝易发生进行性肝损伤。在肝脂肪变性发展过程中涉及的许多机制中,胰岛素介导的脂肪组织代谢失调是主要因素。特别是,增强脂肪组织脂解产生的游离脂肪酸及其向肝脏的输送,最终导致肝脂肪变性。脂肪-肝脏轴受激素调节,特别是胰岛素和脂联素。在最近的研究中,我们证明了酒精诱导的血清生长激素释放肽水平升高会损害胰岛β细胞的胰岛素分泌。随之而来的循环胰岛素水平降低促进脂肪分解和脂肪酸向肝脏的动员,最终导致肝脂肪变性。由于包括脂肪组织在内的许多组织都表达生长激素释放肽受体,我们假设生长激素可能直接影响脂肪细胞的能量代谢。我们有令人兴奋的新初步数据表明,用生长激素处理前体 3T3-L1 脂肪细胞会损害脂肪细胞分化并抑制组织中脂质积累,该组织旨在以脂肪的形式储存能量。我们还观察到,生长激素处理分化的脂肪细胞会显著抑制脂联素的分泌,脂联素是一种具有保护肝脏作用的激素,可减少脂质合成并促进脂质氧化。我们观察到用生长激素受体拮抗剂治疗乙醇喂养的大鼠可显著增加血清脂联素水平,这一结果证实了这些结果。有趣的是,在脂肪细胞中,生长激素还会增加白细胞介素 6(IL-6)和 CCL2(趋化因子 [C-C 基序]配体 2)的分泌,这些细胞因子可促进肝脏炎症和肝病进展。总之,血清生长激素水平的酒精诱导升高通过增加从脂肪组织释放的用于肝摄取的游离脂肪酸,以及通过改变脂联素和细胞因子的分泌,扰乱脂肪-肝脏相互作用并促进肝脂肪变性。总的来说,我们的数据表明,靶向生长激素的活性可能是一种有效的治疗策略。

相似文献

1

引用本文的文献

1
Effect of aging on the development and progression of alcohol-associated liver disease.衰老对酒精性肝病发生发展的影响。
Alcohol Clin Exp Res (Hoboken). 2025 Jul;49(7):1412-1423. doi: 10.1111/acer.70086. Epub 2025 Jun 3.
2
Immunology and treatments of fatty liver disease.脂肪肝疾病的免疫学与治疗方法
Arch Toxicol. 2025 Jan;99(1):127-152. doi: 10.1007/s00204-024-03920-1. Epub 2024 Dec 18.

本文引用的文献

2
Recent trends in the epidemiology of alcoholic liver disease.酒精性肝病的流行病学近期趋势。
Clin Liver Dis (Hoboken). 2013 Apr 24;2(2):53-56. doi: 10.1002/cld.168. eCollection 2013 Apr.
5
Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies.非酒精性脂肪性肝病:抗糖尿病药物治疗综述
J Clin Transl Hepatol. 2018 Jun 28;6(2):168-174. doi: 10.14218/JCTH.2017.00050. Epub 2018 Mar 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验